Account Info
Log Out
English
Back
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh Refresh
Loading
History record delete
    Quotes All >
      News All >
        Log in to access Online Inquiry
        Back to the Top
        Weight-loss drugmakers report strong earnings: Boon or bane?
        Event Description
        Ended
        While the weight-loss drug frenzy spread all over the world, the two star pharmaceutical manufacturers, $Novo-Nordisk A/S (NVO.US)$ and Show More
        While the weight-loss drug frenzy spread all over the world, the two star pharmaceutical manufacturers, $Novo-Nordisk A/S (NVO.US)$ and $Eli Lilly and Co (LLY.US)$ , were driven to record highs. Both of them announced quarterly earnings before the bell on Thursday, and they didn't disappoint investors.

        Denmark-based Novo reported $8.4 billion in revenue in the past three months, a 29% increase from a year ago. It's third-quarter profits jumped 56% YoY, fueled by surging demand for its obesity drugs Ozempic and Wegovy. Eli Lilly's third-quarter revenue was $9.5 billion, up 37% YoY; adjusted earnings per share of 10 cents, and the market expects a loss of 13 cents per share.

        Lilly’s share price was up 5% in early trading Thursday and has gained about 60 percent so far this year, giving the company a stock-market value of roughly $550 billion — the largest among U.S. drugmakers. Novo shares were up about 4 percent Thursday and have increased nearly 50 percent this year. What are your thoughts?
        Views
        117K
        Posts
        245
        Join event
        Latest
        Hot